Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHarvard Bioscience Inc

Harvard Bioscience Inc

Healthcare Medical Instruments & Supplies
PortfolioPortfolio WatchlistWatchlist
Company price
9.09 USD 0.73 ( 8.73%)
Last update at 2026-11-09T21:00:00Z
VOLUME
46776
Market Cap
138.11M

Momentum Score

…

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.35
Low
9.32
High
52 Week Price Range
3.09
Low
6.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Harvard Bioscience, Inc. designs and sells life‑science instruments and consumables used by academic, pharmaceutical and biotech laboratories for physiology, tissue and drug‑discovery applications. Long‑term growth may be supported by rising global R&D spending, increasing demand for tools used in biologics and cell‑therapy research, and expansion of consumable and service revenue, which may make the company attractive to investors seeking exposure to the research‑tools market.

Key risks include reliance on cyclical R&D budgets, intense competition from larger instrument suppliers, execution risk in new‑product commercialization and potential supply‑chain or integration challenges.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.36
Dividend Yield
-
Revenue TTM
106.79M
Revenue Per Share
2.50
Gross Profit TTM
62.29M
Debt / Equity
0.59
ROE
-12.20%
Net Debt
38.49M
ROCE
-6.47%
Diluted EPS TTM
-0.20

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -9.18M -0.14M -7.29M -5.50M -8.52M
Net income -9.52M -0.29M -7.81M -4.69M -3.46M
Selling general administrative 24.49M 24.30M 23.51M 22.76M 21.38M
Selling and marketing expenses 25.04M 24.64M 19.92M 23.26M 24.44M
Gross profit 60.82M 67.65M 58.04M 64.32M 63.18M
Reconciled depreciation 7.58M 7.62M 7.63M 7.73M 7.88M
Ebit -7.17M 1.40M -0.58M 1.47M -3.30M
Ebitda -1.04M 7.24M 5.12M 7.22M 2.09M
Depreciation and amortization 6.12M 5.84M 5.71M 5.75M 5.38M
Non operating income net other 0.30M -0.67M -2.68M -0.47M -3.59M
Operating income -7.17M 1.40M -0.58M 1.47M 0.98M
Other operating expenses 120.50M 116.84M 101.88M 114.34M 119.79M
Interest expense 2.25M 1.54M 4.83M 5.41M 5.37M
Tax provision 0.34M 0.15M 0.52M -0.81M -3.68M
Interest income - - - 5.41M 5.22M
Net interest income -2.55M -1.54M -4.83M -5.41M -5.37M
Extraordinary items - - - - 1.38M
Non recurring -0.23M - - 1.46M -
Income tax expense 0.34M 0.15M 0.52M -0.81M -3.68M
Total revenue 113.33M 118.90M 102.10M 116.18M 120.77M
Total operating expenses 67.98M 65.59M 57.82M 62.48M 62.20M
Cost of revenue 52.52M 51.25M 44.06M 51.85M 57.59M
Total other income expense net -2.01M -1.54M -6.71M -6.97M -4.13M
Discontinued operations - - - - 1.38M
Net income from continuing ops -9.52M -0.29M -7.81M -4.69M -4.30M
Net income applicable to common shares -9.52M -0.29M -7.81M -4.69M -2.92M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 137.37M 145.36M 162.34M 156.25M 164.87M
Intangible assets 16.04M 21.01M 27.39M 33.15M 38.41M
Other current assets 3.94M 3.47M 4.34M 3.35M 2.47M
Total liab 64.29M 73.14M 78.94M 79.57M 83.18M
Total stockholder equity 73.07M 72.22M 83.40M 76.68M 81.69M
Deferred long term liab - 0.59M - 1.90M 1.97M
Other current liab 6.00M 9.62M 12.90M 9.59M 9.12M
Common stock 0.43M 0.45M 0.45M 0.44M 0.44M
Capital stock 0.43M 0.45M 0.45M 0.44M 0.44M
Retained earnings -145.60M -142.19M -132.67M -132.39M -124.58M
Other liab - 1.60M 8.53M 12.23M 2.12M
Good will 57.06M 56.26M 57.69M 58.59M 57.38M
Other assets - 7.78M 12.27M 8.85M 2.27M
Cash 4.28M 4.51M 7.82M 8.32M 8.34M
Total current liabilities 26.54M 23.25M 25.32M 21.05M 25.31M
Current deferred revenue 7.71M 3.37M 4.27M 3.77M 3.95M
Net debt 38.49M 42.32M 40.51M 39.69M 45.48M
Short term debt 7.28M 3.81M 3.23M 1.72M 6.90M
Short long term debt 5.86M 3.81M 3.23M 1.72M 6.90M
Short long term debt total 42.77M 46.82M 48.33M 48.01M 53.82M
Other stockholder equity 232.44M 229.01M 225.65M 221.69M 218.52M
Property plant equipment - 3.37M 3.42M 3.96M 4.78M
Total current assets 49.04M 51.12M 61.58M 51.70M 53.57M
Net tangible assets - 72.22M 83.40M -15.06M 24.31M
Net receivables 16.10M 16.70M 21.83M 17.77M 20.70M
Long term debt 30.70M 43.01M 45.09M 46.29M 46.92M
Inventory 24.72M 26.44M 27.59M 22.26M 22.06M
Accounts payable 5.55M 6.45M 4.91M 5.97M 5.34M
Accumulated other comprehensive income -14.19M -15.05M -10.03M -13.07M -12.69M
Common stock total equity - 0.45M 0.45M 0.44M 0.44M
Retained earnings total equity - -142.19M -132.67M -132.39M -124.58M
Treasury stock - - - -10.67M -10.67M
Non currrent assets other 6.04M 13.60M 12.27M 8.85M 10.74M
Non current assets total 88.33M 94.24M 100.76M 104.55M 111.30M
Capital lease obligations 6.21M 7.42M 8.63M 9.59M 10.65M
Long term debt total - - - 46.29M 46.92M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.59M -1.34M -1.40M -0.23M -53.80M
Change to liabilities -1.94M -0.10M 0.48M -3.97M -1.31M
Total cashflows from investing activities -1.59M -1.34M -1.40M -0.23M -53.80M
Net borrowings -1.79M -0.05M -7.49M -7.40M 48.50M
Total cash from financing activities -2.84M -0.25M -7.97M -7.63M 53.05M
Change to operating activities -0.07M -10.19M 4.11M -1.40M -6.13M
Net income -9.52M -0.29M -7.81M -4.69M -3.46M
Change in cash -3.31M -0.50M -0.02M 0.16M 2.44M
Begin period cash flow 7.82M 8.32M 8.34M 8.17M 5.73M
End period cash flow 4.51M 7.82M 8.32M 8.34M 8.17M
Total cash from operating activities 1.15M 1.26M 9.33M 8.05M 2.34M
Depreciation 7.58M 7.62M 7.63M 7.73M 7.88M
Other cashflows from investing activities - -0.15M -0.25M 0.99M -52.81M
Change to inventory 0.25M -5.86M 0.41M 3.26M 2.55M
Change to account receivables 4.78M -4.29M 3.10M 0.47M -2.79M
Sale purchase of stock 0.58M 3.31M - -0.22M 4.56M
Other cashflows from financing activities 6.17M 3.95M 60.84M 4.30M 68.69M
Change to netincome 4.41M 4.17M 5.15M 4.97M -1.05M
Capital expenditures 1.59M 1.34M 1.15M 1.22M 0.99M
Change receivables 4.78M -4.29M 3.10M 0.47M -2.92M
Cash flows other operating 1.43M 5.58M 5.68M 5.63M 5.46M
Exchange rate changes - - - - 0.30M
Cash and cash equivalents changes -3.27M -0.34M -0.04M 0.19M 2.44M
Change in working capital 2.72M -10.19M 4.11M 0.04M -1.68M
Stock based compensation 4.41M 4.17M 3.65M 3.03M 3.04M
Other non cash items -3.62M 0.28M 1.90M 2.32M -0.58M
Free cash flow -0.44M -0.08M 8.18M 6.83M 1.36M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HBIO
Harvard Bioscience Inc		 0.73
8.73%		 9.09 - 14.93 1.64 2.52 1.99 27.76
ISRG
Intuitive Surgical Inc		 7.49
1.65%		 460.29 43.30 31.35 12.25 7.35 11.63 30.22
ESLOF
EssilorLuxottica Société anonyme		 0.14
0.07%		 213.00 44.84 27.62 4.07 2.49 3.71 16.04
ESLOY
Essilor International SA		 -0.55
0.51%		 107.20 41.68 27.25 3.94 2.45 3.71 16.04
BDX
Becton Dickinson and Company		 -
-%		 215.25 31.62 13.76 2.25 2.04 2.93 13.40

Profile*

Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.

84 October Hill Road, Holliston, MA, United States, 01746

508 893 8999

https://www.harvardbioscience.com

391

Name Title Year Born
Mr. James W. Green Pres, CEO & Chairman 1958
Mr. Michael A. Rossi Chief Financial Officer 1974
Mr. Kenneth Fletcher Olson Exec. Officer 1962
Mr. David Balcom Sr. VP of Operations NA
Mr. John J. Fry Chief Legal Counsel & Corp. Sec. 1961
Mr. Ryan Wallace Sr. VP of Global Sales - Preclinical Systems NA
David Sirois Director of Corp. Accounting & SEC Reporting NA
Mr. James W. Green President, CEO & Chairman 1958
Mr. David Balcom Senior Vice President of Operations NA
Mr. John J. Fry Chief Legal Counsel & Corporation Secretary 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 5.04
+14.17%
FDY
CAD 4.42
+12.18%
UCU
CAD 2.38
+11.21%
PDN
CAD 8.39
+11.13%
DIV
CAD 3.64
-10.57%
TOI
CAD 99.55
-4.99%
BSX
CAD 0.82
-4.65%
CSU
CAD 3367.07
-4.52%
LMN
CAD 26.82
-4.52%

Equity Sectors*

  • Basic Materials

    +5.01%

  • Communication Services

    -0.62%

  • Consumer Cyclical

    +1.25%

  • Consumer Defensive

    +0.14%

  • Energy

    +1.86%

  • Financial Services

    +1.87%

  • Healthcare

    +1.10%

  • Industrials

    +3.75%

  • Real Estate

    +0.53%

  • Technology

    +2.31%

  • Utilities

    +0.99%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…